Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP. It includes our own residential service and selected Swiss clinical pathways. The comparison is intended to clarify roles rather than award a universal best-provider ranking. Hospital, outpatient and luxury residential services have different capabilities and access requirements. All proposed treatment must be checked for the individual. [1]

Someone who develops physical dependence after taking a prescribed benzodiazepine may need help with a medication change without having a substance use disorder. Someone else may experience impaired control and continue harmful use despite consequences. The same medicine can appear in both situations, but the treatment questions differ. The joint guideline cautions against assuming that dependence establishes addiction. [2]

A Swiss resident may have a primary-care clinician, psychiatrist and pain specialist involved at different times. Begin by establishing who has the current overview. Bring exact products, formulations and actual use, including nonprescribed supplies and alcohol. Explain which symptoms the medication helps as well as its unwanted effects. The point is to support an accurate assessment, not to persuade a provider to accept a predetermined residential plan.

For sedatives, an abrupt change can create serious withdrawal risk. Do not stop a benzodiazepine to meet an assumed admission requirement. Combining it with opioids or alcohol also needs explicit review. Seizures, breathing difficulty, severe confusion, suspected overdose or immediate danger require urgent local medical care rather than waiting for a residential admissions response. [3]

PUK Zurich describes addiction and dual-diagnosis care across outpatient, day and inpatient settings, including withdrawal treatment. Its published adult target group and preference for Zurich canton residents should be checked against the individual’s circumstances. HUG describes integrated addiction and psychiatric care with outpatient and hospital options in the Geneva area. Neither entry should be treated as a promise of immediate admission, funding or a particular room arrangement. [4] [5]

These local routes may be particularly useful when the clinical plan requires repeated review or close coordination with Swiss prescribers. A residential stay in Mallorca is a separate option when the required medical arrangements are compatible with that setting. Ask what would be gained by leaving the existing care network and how the connection will be maintained throughout the stay.

Opioid medication

If opioid pain treatment has become problematic, assessment should consider pain, function, dependence and possible opioid use disorder together. For diagnosed opioid use disorder, the CDC recommends medication treatment and advises against detox alone because of return-to-use and overdose risks. When comparing programs, ask how appropriate opioid care is provided or arranged and who will continue it in Switzerland. This clinical principle is not a claim about a particular provider’s prescribing capability. [7]

Anxiety medicines

For benzodiazepines, the plan should address the original anxiety or other indication as well as withdrawal risk and any harmful use. The medical process may extend beyond a residential stay. Ask how symptoms will be reviewed if they change, which clinician is responsible and whether specialist support is required. A set booking duration should not become the deadline for completing a medication change. [2]

Sleep-related prescriptions

When a sleeping medicine is central to the concern, ask whether treatment includes an assessment of insomnia and daytime functioning. Different sleep products have different profiles, and a general addiction label may not explain the problem. NHLBI guidance describes CBT-I as a usual first treatment for persistent insomnia. Verify access to appropriate sleep expertise rather than infer it from a calm setting or a program’s wellness activities. [8]

Other medication concerns

Some people need a second opinion or an organized prescribing review rather than addiction rehabilitation. Antidepressant withdrawal, for example, should not automatically be described as addiction. COGNIFUL’s medication information recognizes that the original condition and actual use determine the appropriate assessment. A service should be able to explain when its own residential format is unnecessary or insufficient. [1]

Identify the canton and clinician to which the person will return. A recommendation for follow-up is only useful if an appropriate service has accepted the role. Where treatment involves several languages, ask for a medication summary and clinical handover that the receiving professionals can use. Exact formulation details should survive translation; a broad description such as anxiety tablets does not provide enough information.

If insurance may contribute to Swiss or overseas treatment, seek a decision for the specific proposed service. Do not assume that a private residential program abroad will be treated like a local hospital admission. Ask what documentation is needed and who is responsible for payment if reimbursement is declined. COGNIFUL’s programs are generally self-pay, with no direct insurer billing or guaranteed reimbursement. [6]

Privacy arrangements should distinguish practical coordination from medical consent. A family office or assistant may organize travel and payment without receiving clinical details. A relative may participate in selected discussions without deciding medication changes. Ask the provider how these different roles are recorded and how the client can speak privately with the treating professional.

A good proposal explains why time in a residence would help with this person’s difficulties. It may allow sustained work on emotional distress, medication-seeking patterns, family conflict or daily routines that have become hard to change at home. Those aims should be connected to an assessed formulation. They do not replace a medical plan for the prescription itself.

Request practical goals that can be reviewed. Examples include a clearer route for prescription questions, more honest communication with clinicians, a response to cravings, and a realistic plan for work or travel. Ask how the team would respond if the initial formulation proves incomplete. Treatment should leave room for new information rather than interpret every setback as a lack of motivation.

COGNIFUL is based in Mallorca, Spain, and considers prescription-medication concerns through its suitability process. It does not present every prescription question as addiction or every withdrawal concern as a residential admission. Medical detoxification, acute psychiatric symptoms and other medical requirements may call for a different service first. The practical starting point is an assessment of whether the shared residential setting can meet the person’s current needs. [1] [9]

Both COGNIFUL Premier and Premier Plus operate within a residence for a maximum of four clients at any time, each with a private suite. Clinical and bodywork sessions are individual. The setting, chef, personal manager, other holistic sessions, excursions and activities are shared. This is personal clinical work in a small shared residence; the capacity does not establish a dedicated team for one client or a specified level of medical monitoring. [6]

For a Swiss resident, a proposed stay should make clear how the Mallorca team and existing clinicians would communicate with consent. Ask who would review medication, where any specialist work would occur and who takes responsibility for prescriptions. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Clinical assessment determines the appropriate care plan and setting. In some cases, treatment may begin with an initial 1–3 days in a partner hospital for observation and stabilization before continuing at COGNIFUL. The pathway is planned around each person’s medical needs. Essential arrangements should be confirmed before travel. [9] The medical plan, prescribing responsibilities and any additional specialist support are confirmed individually.

COGNIFUL Premier and Premier Plus both include assessment, a personal plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is agreed individually. Stays typically range from four to twelve weeks and are individually reviewed. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [6] View program fees

Ask the written proposal to translate those inclusions into your own priorities. Which family conversations are relevant? What transition work is needed before returning to Switzerland? Which professionals are expected to contribute? What is included in the aftercare and what requires a separate agreement? The higher-priced option should be evaluated through those answers rather than a presumption of superior clinical results.

The proposal also confirms the overall cost and possible extras. External medical care, travel, medication and local follow-up should be clarified separately. Before discharge, identify a Swiss clinician who has accepted the next appointment and any ongoing prescribing role. COGNIFUL’s continuing-care planning supports preparation for home, but it should not be interpreted as universal remote prescribing across national borders. [10]

Prepare a short chronology of prescriptions, relevant diagnoses, changes in actual use and previous treatment attempts. Include what worked. If there were episodes of withdrawal, overdose or hospital care, describe them plainly and provide the available records. This can help clinicians distinguish a new addiction-treatment need from a longstanding medication-review problem.

Also write down the questions that matter to you: whether pain will be treated, how sleep will be addressed, who can speak to your family, or whether you can maintain essential responsibilities. These concerns belong in the clinical conversation. A suitable plan should acknowledge them while remaining clear about the medical limits of the proposed setting.

Does choosing treatment abroad replace my Swiss prescriber?

No automatic transfer occurs. The roles during and after the stay need explicit agreement. Confirm who will issue prescriptions, who will review changes and whether the receiving Swiss clinician has accepted the plan before relying on it. [9]

Should a person with dependence be labeled addicted?

Not without assessment. Physical dependence and a substance use disorder are distinct concepts, although they can coexist. The treatment recommendation should reflect the actual pattern of use, harms and medical needs. [2]

Does COGNIFUL have a Swiss treatment location?

The verified residential location is Mallorca, Spain. This guide is written for Swiss residents considering local and overseas options. A Swiss contact or group connection should not be mistaken for a local COGNIFUL residence. [6]

What makes a follow-up plan credible?

Named professionals, accepted responsibilities, confirmed appointments and a clear route for concerns. A directory of possible clinicians is a starting point, not a completed handover. Medication and psychological treatment should remain connected where both are needed. [10]

COGNIFUL admissions can discuss the Mallorca program and explain the information needed for clinical suitability review. Share the prescription history and existing Swiss care arrangements. The decision should establish where medical needs will be managed and whether a residential phase adds useful treatment for the person. [6]

1. Prescription medication concerns and residential treatment — COGNIFUL.
2. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
3. Benzodiazepine safety communication — US Food and Drug Administration.
4. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich.
5. Addictology service care options — Geneva University Hospitals.
6. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
7. Opioid use disorder: treating — Centers for Disease Control and Prevention.
8. Insomnia treatment — National Heart, Lung, and Blood Institute.
9. Clinical scope, suitability and care coordination — COGNIFUL.
10. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.